表紙
市場調査レポート

インドの有効成分 (API) 市場の機会

Indian API Market Outlook 2022

発行 RNCOS E-Services Pvt. Ltd. 商品コード 341900
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
インドの有効成分 (API) 市場の機会 Indian API Market Outlook 2022
出版日: 2016年07月01日 ページ情報: 英文 65 Pages
概要

当レポートでは、インドのAPI市場について調査分析し、市場の潜在性と将来の成長機会、主要促進要因と課題、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 インドのAPI産業の見通し

  • 世界のAPI市場におけるインドのシェア
  • インドにおけるAPIの消費の見通し
  • インド市場における主なAPI

第4章 促進要因と課題

  • 促進要因
  • 課題

第5章 市場区分

  • 製造の種類別
  • APIの種類別
  • 治療分野別

第6章 合併と買収

第7章 政府の取り組み

第8章 規制シナリオ

第9章 競合情勢

  • プロファイル
    • Sun Pharma
    • Cipla Limited
    • Biocon
    • Dr. Reddy's Laboratorie
    • Lupin Ltd.
    • Aurobindo Pharma Limited
    • Wockhardt
    • Zydus Cadila
    • Glenmark
    • Jubilant LifeSciences

第10章 市場機会と提言

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

India occupies a significant position in global API market. The Indian API industry has been garnering a lot of attention globally due to the good quality of APIs, which are being manufactured in the country. Recently, the Indian API industry has been witnessing a fabulous growth owing to a number of factors. Some of these factors are patent expiry of blockbuster drugs, increasing demand for low costing generics, and innovation of new generation of APIs. Apart from these, rise in geriatric population, increasing disposable income, rising healthcare expenditure, and increasing incidences of chronic diseases are the other reasons which are driving the growth of the Indian API industry.

According to report on “Indian API Market Outlook 2022”, the Indian API domestic consumption market is forecasted to grow at a CAGR of around 10% from FY 2016-FY 2022. This report provides the share of India in the global API market. Furthermore, it gives information about the current scenario of the Indian API market, and future forecasts related to it. RNCOS analysts have mentioned the major drivers of the market, and factors hindering growth of the market.

The Indian API market has been segmented on the basis of various parameters, such as type of manufacturing, type of API, and type of therapeutic area. Moreover, the report highlights the mergers and acquisitions that have taken place in the Indian API market. The regulatory scenario governing the Indian API market along with the various government initiatives for the development of this industry have also been mentioned in the report. Furthermore, the report provides the details about major mergers and acquisitions occurred in the industry.

The last section of the report discusses about the key players in Indian API industry. A brief business overview and financial information about each of these players has been provided in the report. The recent development and strength-weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. In the end, the areas of opportunities and recommendations for the growth of this industry have also been highlighted in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Indian API market.

Table of Contents

1. Analyst View

2. Research Methodology

3. India API Industry Outlook

  • 3.1. Share of India in Global API Market
  • 3.2. Indian API Domestic Consumption Market Future Outlook
  • 3.3. Major APIs in the Indian API Market

4. Drivers & Challenges

  • 4.1. Drivers
    • 4.1.1. Rising Healthcare Expenditure
    • 4.1.2. Increasing Disposable Incomes
    • 4.1.3. Growing Geriatric Population
    • 4.1.4. Increasing Incidences of Chronic Diseases
    • 4.1.5. Patent Expiry of Blockbuster Drugs
    • 4.1.6. Increased Consumption of Generic Drugs
    • 4.1.7. Invention of New Generation of APIs
  • 4.2. Challenges
    • 4.2.1. Over dependence on China for Imports
    • 4.2.2. Complex License Renewal Procedure
    • 4.2.3. Few Manufacturers in the API Industry
    • 4.2.4. Inadequate Infrastructure Facilities
    • 4.2.5. Lack of Government Support
    • 4.2.6. Stringent Regulatory Policies

5. Market Segmentation

  • 5.1. By Type of Manufacturing
  • 5.2. By Type of API
  • 5.3. By Type of Therapeutic Area

6. Mergers and Acquisitions

7. Government Initiatives

  • 7.1. Katoch Committee
  • 7.2. 'Make in India' Campaign
  • 7.3. Pharma Vision 2020
  • 7.4. Establishment of New NIPERs
  • 7.5. Set-Up of Reviewing Committee
  • 7.6. Launch of Fund by Government

8. Regulatory Scenario

9. Competitive Landscape

  • 9.1. Sun Pharma
  • 9.2. Cipla Limited
  • 9.3. Biocon
  • 9.4. Dr. Reddy's Laboratories
  • 9.5. Lupin Limited
  • 9.6. Aurobindo Pharma Limited
  • 9.7. Wockhardt
  • 9.8. Zydus Cadila
  • 9.9. Glenmark Pharmaceuticals
  • 9.10. Jubilant LifeSciences

10. Opportunities and Recommendations

  • 10.1. Opportunities
  • 10.2. Recommendations

List of Figures:

  • Figure 3-1: India API Market Trade (%), FY 2016
  • Figure 3-2: Share of India in Global API Market (%), FY 2016
  • Figure 3-3: Indian API Domestic Consumption Market (Billion US$), FY 2016-FY 2022
  • Figure 4-1: Healthcare Expenditure (US$ per head), 2012-2016
  • Figure 4-2: Personal Disposable Income (Trillion US$), 2012-2016
  • Figure 4-3: Indian Population - 60 years or above (Million), 2015 & 2030
  • Figure 4-4: India - Number of People with Diabetes (Million), 2015 & 2040
  • Figure 4-5: India - Number of New Cancer Cases (Million), 2015 & 2020
  • Figure 5-1: Share of Captive and Merchant Market APIs in Indian API Market (%), FY 2016
  • Figure 5-2: Share of Chemical/Small Molecule and Biotech APIs in Indian API Market (%), FY 2016
  • Figure 5-3: Share of APIs by their Application in Therapeutic Areas in Indian API Market (%), FY 2016
  • Figure 8-1: API License Procedure

List of Tables:

  • Table 3-1: Major APIs in the Indian API Market
  • Table 4-1: List of Blockbuster Drugs Losing Patent (2016-2022)
  • Table 4-2: API Import from China (Billion US$), FY 2012 to FY 2015
  • Table 6-1: Mergers and Acquisitions in Indian Pharmaceutical Industry (2014-2016)
  • Table 9-1: Sun Pharma - Net Sales (Billion US$), FY 2013, FY 2014 & FY 2015
  • Table 9-2: Cipla Limited - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 9-3: Biocon - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 9-4: Dr. Reddy's Laboratories - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 9-5: Lupin Limited - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 9-6: Aurobindo Pharma Limited - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 9-7: Wockhardt - Total Sales (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 9-8: Zydus Cadila - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 9-9: Glenmark - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 9-10: Jubilant LifeSciences - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Back to Top